Hormonal
Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.
If you have successfully lost weight using 2.4 mg of weekly semaglutide combined with lifestyle changes, stopping the medication will likely cause you to regain most of that weight. To maintain your weight loss, you must continue the weekly injections indefinitely, as the drug's hormonal effect on appetite control is necessary to counteract the body's tendency to regain weight.
Among adults with overweight or obesity who completed a 20-week run-in period with subcutaneous semaglutide, 2.4 mg once weekly, maintaining treatment with semaglutide compared with switching to placebo resulted in continued weight loss over the following 48 weeks.
Why this rating
Large-scale (n=803), randomized, double-blind, placebo-controlled Phase 3 clinical trial published in JAMA.
Source
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
Domenica Rubino et al. · JAMA · 2021
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →